Moderna Dips to $248.10 as Hedging Rises Despite Strong Q3 Beat

Moderna Inc. shares fell $2.73 to close near $248.10 on November 11, 2026. The decline came alongside an elevated put/call ratio of 2.79, well above the typical 1.06 average, according to GuruFocus. That options activity indicated that traders were seeking downside protection, even as 30-day implied volatility eased 2.46 points to roughly 84.68.

The retreat followed volatile trading on November 10, when different reports tracked wide price swings. Yahoo Finance reported the stock climbed 6.4% to hit a 52-week high of $258.80 after third-quarter results. MarketBeat, however, noted shares fell 6.8% to $250.83 during the session, and TradingKey reported a 4.50% decline amid commercial skepticism surrounding respiratory vaccines and competition.

Moderna recently delivered third-quarter revenue of $1.31 billion, representing a 29.2% increase year over year and topping analyst expectations of $890.25 million. Earnings per share reached $0.38, compared to an expected loss of $1.10. Operating performance benefited from reduced expenses, with research and development spending dropping 27%. Following the results, management raised its 2026 revenue-growth projection to a range of 15% to 25%.

Beyond financial results, investor attention is focused on intismeran, Moderna's personalized cancer therapy partnered with Merck. Phase 3 trial data showed a 42% reduction in melanoma recurrence or death. The biotechnology company plans to submit an FDA filing by the close of 2026, which could yield a regulatory decision in 2027.

Despite pipeline progress, market participants have pointed to high valuation multiples and heavy dependence on COVID-related sales. GuruFocus reported a price-to-sales ratio of 40.33, well above Moderna's historical median of approximately 8.6x. In addition, company insiders sold shares worth $81.7 million over the past 12 months with zero purchases, while institutional sentiment remains cautious, holding an average analyst rating of Hold.